LONDON, March 28, 2014 /PRNewswire/ --
On Thursday, March 27, 2014, the
NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones
Industrial Average edged 0.03% lower to 16,264.23, and the S&P
500 closed at 1,849.04, down 0.19%. The losses were broad based
with seven out of ten sectors ending the session in negative. The
S&P 500 Health Care Sector Index finished the day at 671.20,
down 0.13%, and the index has fallen by 2.20% in last one month.
Investor-Edge has initiated coverage on the following equities:
Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ:
AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health
Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and
OPK can be downloaded upon signing up at:
http://www.investor-edge.com/578-register
On Thursday, shares in Prana Biotechnology Ltd declined 5.81% to
close the trading session at $9.89.
The stock recorded a trading volume of 1.92 million shares, as
compared with a three months average volume of 2.06 million shares.
Shares in the company oscillated between $8.80 and $10.36 during the trading session.
Prana Biotechnology Ltd's shares have declined 11.54% in the
previous three trading sessions and 14.22% in the last month, while
the same have surged 41.08% on YTD basis. The stock is trading
above its 50-day and 200-day moving averages. Prana Biotechnology
Ltd's 50-day moving average of $9.76
is above its 200-day moving average of $5.68. Furthermore, the stock is has a Relative
Strength Index (RSI) of 52.79. Sign up today to read free research
on PRAN at:
http://www.investor-edge.com/578-PRAN-28Mar2014.pdf
Amarin Corp PLC's stock recorded a trading volume of 2.74 million
shares, as compared with a three months average volume of 5.00
million shares. The stock ended the day at $1.85, up 5.71% after vacillating between
$1.71 and $1.85. Amarin Corp PLC's
shares have gained 5.11% in the previous three trading sessions and
3.93% in the last one month, while the same have declined 6.09% on
YTD basis. The company's stock is trading above its 50-day moving
average. Amarin Corp PLC's 200-day moving average of $3.75 is above its 50-day moving average of
$1.83. Additionally, shares of the
company have an RSI of 44.75. Sign up today to read free research
on AMRN at:
http://www.investor-edge.com/578-AMRN-28Mar2014.pdf
On Thursday, shares in United Therapeutics Corp. finished the
session 0.26% higher at $93.86. A
total of 1.06 million shares were traded, which is above the three
months average volume of 0.76 million. The stock fluctuated between
$91.34 and $95.57 during the session.
Shares of the company traded at a PE ratio of 28.62. United
Therapeutics Corp.'s stock fell 0.27% in the previous three trading
sessions, 8.21% in the last one month, and 17.00% on YTD basis. The
stock is trading above its 200-day moving average. United
Therapeutics Corp.'s 50-day moving average of $101.57 is above its 200-day moving average of
$86.57. Moreover, the stock indicated
an RSI 37.64. Sign up today to read free research on UTHR at:
http://www.investor-edge.com/578-UTHR-28Mar2014.pdf
Shares in OPKO Health Inc. reported a trading volume of 2.14
million shares, as compared with a three months average volume of
3.13 million shares. The stock ended the day at $9.05, down 0.33% and at an intraday range of
$8.88 and $9.24. OPKO Health Inc.'s shares have fallen by
2.58% in the previous three trading sessions and 3.21% in the last
month, but they have gained 7.23% on YTD basis. The stock is
trading above its 50-day and 200-day moving averages. OPKO Health
Inc.'s 200-day moving average of $8.82 is above its 50-day moving average of
$8.79. Furthermore, the stock
indicated an RSI of 46.82. Sign up today to read free research on
OPK at:
http://www.investor-edge.com/578-OPK-28Mar2014.pdf
EDITOR'S NOTES:
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge
